^
    Back
    Association details:
    Biomarker:EGFR C797S
    Cancer:Non Small Cell Lung Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).

    Published date:
    05/26/2022
    Excerpt:
    ECOG PS 0-1 patients (pt) with EGFR-mutant NSCLC were enrolled after OSI resistance. AFA was prescribed at 30-40 mg QD, and BEV was administered at 15 mg/kg tri-weekly until progression....Among 6 C797S pts, 1 CR, 4 SD, and 1 PD were confirmed….AFA+BEV after OSI resistance demonstrated moderate efficacy and favorable safety. A small portion of C797S pts exhibited the sensitivity.
    DOI:
    10.1200/JCO.2022.40.16_suppl.9117